Hang Zhou Zhi Xing Zhi Yao You Xian Gong Si

The main purpose of the study is to use GlaxoSmithKline's salmeterol and fluticasone inhalation powder (Seretide@) as the reference preparation and the salmeterol and fluticasone inhalation powder developed by Hangzhou Zhixing Pharmaceutical Co., Ltd. as the test preparation. Through a fasting, single-center, randomized, open, single-dose, two-cycle crossover clinical study, the bioequivalence of the two preparations in the fasting state is evaluated. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

The main purpose of the study is to use GlaxoSmithKline's salmeterol and fluticasone inhalation powder (Seretide®) as the reference preparation and the salmeterol and fluticasone inhalation powder developed by Hangzhou Zhixing Pharmaceutical Co., Ltd. as the test preparation. Through a fasting, single-center, randomized, open, single-dose, two-period crossover clinical study, the bioequivalence of the two preparations in the fasting state is evaluated. The secondary purpose of the study is to observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

The main purpose of the study is to use the fluticasone propionate suspension for nebulized inhalation (FLIXOTIDE NEBULES) of GlaxoSmithKline Australia Pty Ltd. as the reference preparation and the fluticasone propionate suspension for nebulized inhalation developed by Hangzhou Zhixing Pharmaceutical Co., Ltd. as the test preparation. Through a single-center, randomized, open, single-dose, two-period, double-crossover clinical study, the bioequivalence of the two preparations in the fasting state is evaluated. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.